This is the authors' abstract. We don't add key points for this paper.
The gene encoding phosphatidylinositol 3-kinase catalytic subunit α-isoform ( PIK3CA , p110α ) is frequently activated by mutation in human cancers. Based on detection in some breast cancer precursors, PIK3CA mutations have been proposed to have a role in tumor initiation. To investigate this hypothesis, we generated a novel mouse model with a Cre-recombinase regulated allele of p110α (myristoylated- p110α, myr- p110α ) along with p53 fl/fl deletion and Kras G12D also regulated by Cre-recombinase. After instillation of adenovirus-expressing Cre-recombinase into mammary ducts, we found that myr- p110α accelerated breast tumor initiation in a copy number-dependent manner. Breast tumors induced by p53 fl/fl ; Kras G12D with no or one copy of myr- p110α had predominantly sarcomatoid features, whereas two copies of myr- p110α resulted in tumors with a carcinoma phenotype. This novel model provides experimental support for importance of active p110α in breast tumor initiation, and shows that the amount of PI3K activity can affect the rate of tumor initiation and modify the histological phenotype of breast cancer.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sheen et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: